Peng Xin, Sun Jingyue, Long Yao, Xiao Desheng, Zhou Jianhua, Tao Yongguang, Liu Shuang
Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education; Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, 410078, People's Republic of China.
NHC Key Laboratory of Carcinogenesis of Ministry of Health (Central South University), Cancer Research Institute; School of Basic Medicine, Central South University, Changsha, Hunan, 410078, People's Republic of China.
Onco Targets Ther. 2021 Mar 1;14:1517-1529. doi: 10.2147/OTT.S273195. eCollection 2021.
Gastric adenocarcinoma is one of the most important causes of cancer death and lacks effective treatment. Eighty-four gastric adenocarcinoma tissue samples along with the clinical information were collected. After analyzing the expression of HOXC11 and LSH in the gastric adenocarcinoma tissues, we explored the prognosis of patients and its correlation with clinical characteristics. Both HOXC11 and LSH were over-expressed in MKN-45 cell lines to verify the effect of high expression of HOXC11 and LSH on GAC.
The expression of HOXC11 and LSH in 84 cases with gastric adenocarcinoma (GAC) was detected via immunohistochemistry, including 17 cases in stage I, 7 cases in stage II, 27 cases in stage III and 33 cases in stage IV. The expression levels of HOXC11 and LSH, and the clinicopathological characteristics of the samples, were also studied. Cell proliferation, migration, cell cycle and apoptosis assays were utilized for demonstrating malignancy of HOXC11 and LSH over-expressed cells.
Among 84 GAC pathological samples, 12 high HOXC11 expression, and 72 showed low expression; 54.8% (46/84) high LSH expression, and 45.2% (38/84) exhibited low expression. Survival analysis of the Kaplan-Meier plotter gastric cancer datasets showed that subjects with low expression of HOXC11 and LSH had a longer survival time, with a median survival time of 40.2 and 36.4 months, while the subjects with high HOXC11 and LSH expression were only 20.5 and 10 months, respectively. Meanwhile, HOXC11 and LSH over-expressed cells showed a stronger proliferous and migratory ability, and a sped up cell cycle.
The high expression level of HOXC11 and LSH both manifested the poor survival prognosis of GAC patients, and more pronounced malignant phenotype in GAC cells indicated that HOXC11 and LSH can be a strong predictive factor of inferior disease-free survival. From this, we can consider that HOXC11 and LSH both have significant status in GAC stage and survival prediction.
胃腺癌是癌症死亡的最重要原因之一，且缺乏有效的治疗方法。我们收集了84份胃腺癌组织样本及相关临床信息。在分析了HOXC11和LSH在胃腺癌组织中的表达情况后，我们探究了患者的预后及其与临床特征的相关性。同时，在MKN-45细胞系中使HOXC11和LSH均过表达，以验证HOXC11和LSH高表达对胃腺癌的影响。
采用免疫组织化学法检测84例胃腺癌（GAC）患者中HOXC11和LSH的表达情况，其中I期17例，II期7例，III期27例，IV期33例。同时研究HOXC11和LSH的表达水平以及样本的临床病理特征。利用细胞增殖、迁移、细胞周期和凋亡检测来证明HOXC11和LSH过表达细胞的恶性程度。
在84份GAC病理样本中，12份HOXC11高表达，72份低表达；46份（54.8%，46/84）LSH高表达，38份（45.2%，38/84）低表达。Kaplan-Meier生存分析显示，HOXC11和LSH低表达的受试者生存时间更长，中位生存时间分别为40.2个月和36.4个月，而HOXC11和LSH高表达的受试者分别仅为20.5个月和10个月。同时，HOXC11和LSH过表达的细胞表现出更强的增殖和迁移能力，且细胞周期加快。
HOXC11和LSH的高表达均表明GAC患者的生存预后较差，且GAC细胞中更明显的恶性表型表明HOXC11和LSH可能是无病生存期较差的有力预测因素。由此，我们可以认为HOXC11和LSH在GAC分期和生存预测中均具有重要地位。
